Celerion’s long-standing CLIA-certified and CAP-accredited clinical laboratories, including its Lincoln site, have paved the way for this achievement, ensuring adherence to the highest standards of laboratory quality and competence for over 25 years. The CLIA certification authorizes Celerion to perform non-waived testing on human specimens, facilitating critical health assessments, diagnoses, and treatment decisions.

With CLIA certification, Celerion’s bioanalytical laboratory expands its capabilities to conduct lab-developed tests in specialized areas such as diagnostic immunology, including ADA and NAb assays. These high-complexity tests play a vital role in patient enrollment for clinical trials, enhancing study precision and efficacy. Moreover, the certification enables Celerion to provide patient-specific results, allowing tailored treatment approaches and optimized therapeutic outcomes.

Dr. Chad Briscoe, Executive Vice President of Global Bioanalytical Sciences at Celerion, remarked, “Achieving CLIA certification is a significant milestone, reflecting our unwavering commitment to quality, precision, and innovation. With this certification, we are poised to deliver enhanced value to our clients and contribute more profoundly to the advancement of healthcare and patient treatment options